# Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

> **NCT07131163** · — · RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Stage II-III Non-small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07131163
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2025-12-28
- **Final completion:** 2025-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131163, "Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07131163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*